Skip to main content
Erschienen in: Cancer Causes & Control 8/2016

05.07.2016 | Brief report

Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade

verfasst von: Meng Yang, Ke Zu, Lorelei A. Mucci, Jennifer R. Rider, Michelangelo Fiorentino, Steven K. Clinton, Massimo Loda, Meir J. Stampfer, Edward Giovannucci

Erschienen in: Cancer Causes & Control | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Higher Gleason grade is associated with prostate cancer mortality; however, there is significant heterogeneity in this association. We evaluated whether vessel morphology, a biomarker of angiogenesis, aided in distinguishing mortality risks among men with high Gleason grading.

Methods

We characterized vessel morphology (area and irregularity) among 511 patients diagnosed with prostate cancer during 1986 to 2000, re-reviewed Gleason grade, and followed men through 2012. Men were grouped according to integrated vessel lumen irregularity and vessel area across Gleason grade. The more angiogenic group was identified as those with more irregular vessel lumen and smaller vessel area. Crude rates (95 % confidence intervals) and survival probability were estimated across Gleason grade and vessel morphology.

Results

During a median 14-year follow-up, 62 men developed bone metastases or died of prostate cancer. Lethality rates were uniformly low within Gleason grade categories 6 and 7(3 + 4), regardless of vessel morphology. However, among men with Gleason grades of 7(4 + 3) or 8–10, the more angiogenic group was associated with fourfold higher risk of lethal outcomes compared to those with less angiogenic potential. Ten-year survival probability ranged from 95 to 74 % according to the extent of vessel morphology (p < 0.0001, log-rank test).

Conclusions

Vessel morphology may aid Gleason grading in predicting prostate cancer mortality risks among men diagnosed with high-grade Gleason cancers.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Stark JR, Perner S, Stampfer MJ et al (2009) Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27:3459–3464CrossRefPubMedPubMedCentral Stark JR, Perner S, Stampfer MJ et al (2009) Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27:3459–3464CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Sakr WA, Grignon DJ, Crissman JD et al (1994) High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases. In Vivo 8:439–443PubMed Sakr WA, Grignon DJ, Crissman JD et al (1994) High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases. In Vivo 8:439–443PubMed
3.
Zurück zum Zitat Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA (2006) How well does the Gleason score predict prostate cancer death? a 20-year followup of a population based cohort in Sweden. J Urol 175:1337–1340CrossRefPubMed Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA (2006) How well does the Gleason score predict prostate cancer death? a 20-year followup of a population based cohort in Sweden. J Urol 175:1337–1340CrossRefPubMed
4.
Zurück zum Zitat Giovannucci E (2011) Commentary: serum lycopene and prostate cancer progression: a re-consideration of findings from the prostate cancer prevention trial. Cancer Cause Control 22:1055–1059CrossRef Giovannucci E (2011) Commentary: serum lycopene and prostate cancer progression: a re-consideration of findings from the prostate cancer prevention trial. Cancer Cause Control 22:1055–1059CrossRef
5.
Zurück zum Zitat Ahmed HU, Arya M, Freeman A, Emberton M (2012) Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? Lancet Oncol 13:e509–e517CrossRefPubMed Ahmed HU, Arya M, Freeman A, Emberton M (2012) Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? Lancet Oncol 13:e509–e517CrossRefPubMed
6.
Zurück zum Zitat Mucci LA, Powolny A, Giovannucci E et al (2009) Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 27:5627–5633CrossRefPubMedPubMedCentral Mucci LA, Powolny A, Giovannucci E et al (2009) Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 27:5627–5633CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Pettersson A, Graff RE, Bauer SR et al (2012) The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomark Prev 21:1497–1509CrossRef Pettersson A, Graff RE, Bauer SR et al (2012) The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomark Prev 21:1497–1509CrossRef
8.
Zurück zum Zitat Graff RE, Pettersson A, Lis RT et al (2016) Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. Am J Clin Nutr 103:851–860CrossRefPubMed Graff RE, Pettersson A, Lis RT et al (2016) Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. Am J Clin Nutr 103:851–860CrossRefPubMed
9.
Zurück zum Zitat West AF, O’Donnell M, Charlton RG, Neal DE, Leung HY (2001) Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br J Cancer 85:576–583CrossRefPubMedPubMedCentral West AF, O’Donnell M, Charlton RG, Neal DE, Leung HY (2001) Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br J Cancer 85:576–583CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364CrossRefPubMed Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364CrossRefPubMed
11.
Zurück zum Zitat Russo G, Mischi M, Scheepens W, De la Rosette JJ, Wijkstra H (2012) Angiogenesis in prostate cancer: onset, progression and imaging. BJU Int 110:E794–E808CrossRefPubMed Russo G, Mischi M, Scheepens W, De la Rosette JJ, Wijkstra H (2012) Angiogenesis in prostate cancer: onset, progression and imaging. BJU Int 110:E794–E808CrossRefPubMed
12.
Zurück zum Zitat Zu K, Mucci L, Rosner BA et al (2014) Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J Natl Cancer Inst. 106:djt430CrossRefPubMedPubMedCentral Zu K, Mucci L, Rosner BA et al (2014) Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J Natl Cancer Inst. 106:djt430CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Li Y, Cozzi PJ (2010) Angiogenesis as a strategic target for prostate cancer therapy. Med Res Rev 30:23–66PubMed Li Y, Cozzi PJ (2010) Angiogenesis as a strategic target for prostate cancer therapy. Med Res Rev 30:23–66PubMed
14.
Zurück zum Zitat Alhusban A, Al-Azayzih A, Goc A, Gao F, Fagan SC, Somanath PR (2014) Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts in vivo through modulation of tumor angiogenesis. J Pharmacol Exp Ther 350:635–645CrossRefPubMedPubMedCentral Alhusban A, Al-Azayzih A, Goc A, Gao F, Fagan SC, Somanath PR (2014) Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts in vivo through modulation of tumor angiogenesis. J Pharmacol Exp Ther 350:635–645CrossRefPubMedPubMedCentral
Metadaten
Titel
Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade
verfasst von
Meng Yang
Ke Zu
Lorelei A. Mucci
Jennifer R. Rider
Michelangelo Fiorentino
Steven K. Clinton
Massimo Loda
Meir J. Stampfer
Edward Giovannucci
Publikationsdatum
05.07.2016
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 8/2016
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-016-0782-x

Weitere Artikel der Ausgabe 8/2016

Cancer Causes & Control 8/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.